Cardiovascular risk assessment and triptans

Headache

Volumn 44, Issue SUPPL. 1, 2004, Pages

  Papademetriou, Vasilios ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Cardiovascular; Migraine; Risk assessment; Triptan

Indexed keywords

SEROTONIN AGONIST;

ALGORITHM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG CONTRAINDICATION; HUMAN; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

CORONARY DISEASE; HUMANS; MIGRAINE DISORDERS; RISK ASSESSMENT; SEROTONIN AGONISTS; VASOCONSTRICTOR AGENTS;

EID: 2542432259     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2004.04106.x     Document Type: Review

References (42)

1. MaassenVanDen Brink A, Saxena PR. Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Headache. 2004;44(suppl 1):S13-S19.
2. Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache. 2004;44(suppl 1):S20-S30.
3. Zolmitriptan [prescribing information]. Wilmington, DE: AstraZeneca; 1999.
4. Rizatriptan [prescribing information]. Whitehouse Station, NJ: Merck; 1999.
5. Sumatriptan Tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2001.
6. Naratriptan [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2001.
7. Frovatriptan [prescribing information]. Craigavon, UK: Elan Pharmaceuticals, Inc; 2001.
8. Young WB, Mannix L, Adelman JU, et al. Cardiac risk factors and the use of triptans: a survey study. Headache. 2000;40:587-591.
9. Shah PK. Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. Prog Cardiovasc Dis. 2002;44:357-368.
10. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation. 1995;92:1355-1374.
11. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
12. Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000;83:361-366.
13. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. Circulation. 1996;94:2013-2030.
14. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
15. Ambrose JA, Winters SL, Stem A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol. 1985;5:609-616.
16. Ambrose JA, Winters SL, Arora R, et al. Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol. 1985;6:1233-1238.
17. Ambrose JA, Hjemdahl-Monsen CE. Arteriographic anatomy and mechanisms of myocardial ischemia in unstable angina. J Am Coll Cardiol. 1987;9:1397-1402.
18. Ambrose JA, Winters SL, Arora RR, et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol. 1986;7:472-478.
19. Little WC, Constantimescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mildto-moderate coronary artery disease? Circulation. 1988;78:1157-1166.
20. Hackett D, Davies G, Maseri A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J. 1988;9:1317-1323.
21. Giroud D, Li JM, Urban P, et al. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol. 1992;69:729-732.
22. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
23. Nazvi TZ, Hachamovitch R, Berman D, et al. Does the presence and site of myocardial ischemia on perfusion scintigraphy predict the occurrence and site of future myocardial infarction in patients with stable coronary artery disease? Am J Cardiol. 1997;79:1521-1524.
24. Meredith IT, Anderson TJ, Uehata A, et al. Role of endothelium in ischemic coronary syndromes. Am J Cardiol. 1993;72:27C-31C.
25. Hoffman BB, Taylor P. Neurotransmission. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 115-154.
26. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol. 1997;20(11 suppl 2):II-11-7.
27. Munzel T, Heitzer T, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. Herz. 1997;22:158-172.
28. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954.
29. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 1998;97:2433-2444.
30. Aikawa M, Libby P. Lipid lowering reduces proteolytic and prothrombotic potential in rabbit atheroma. Ann N Y Acad Sci. 2000;902:140-152.
31. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001;103:276-283.
32. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanable heritable hyperlipidemic rabbits. Circulation. 2001;103:993-999.
33. Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994;90:1935-1941.
34. Shah PK, Nilsson J, Kaul S, et al. Effects of recombinant apoplipoprotein A-I on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 1998;97:780-785.
35. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-I mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice: potential implications for acute plaque stabilization. Circulation. 2001;103:3047-3050.
36. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926-933.
37. Pitt B, Rubenfire M. Risk stratification for the detection of preclinical coronary artery disease. Circulation. 1999;99:2610-2612.
38. Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. J Am Coll Cardiol. 1999:34:1348-1359.
39. The Sixth Report of the Joint National Committee of Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1997. NIH Publication 98-4080.
40. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
41. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
42. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation. 2002;106:388-391.